Generon Announces SPA for US Phase III Trial of Neutropenia Drug

Generon, a Shanghai innovative biopharma, has forged a Special Protocol Assessment with the US FDA for the design of a second Phase III trial of its lead candidate. Gereron believes F-627 (benegrastim), a second-generation recombinant human granulocyte colony-stimulating factor dimer, has best-in-class potential to treat chemotherapy-induced neutropenia. The company is also testing a first-in-class recombinant human interleukin-22 as a treatment for graft-vs-host disease and acute alcoholic hepatitis. More details....

Share this with colleagues:

Original Article: Generon Announces SPA for US Phase III Trial of Neutropenia Drug

More From BioPortfolio on "Generon Announces SPA for US Phase III Trial of Neutropenia Drug"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications